Marshall Wace, LLP Adc Therapeutics Sa Transaction History
Marshall Wace, LLP
- $90.8 Billion
- Q3 2025
A detailed history of Marshall Wace, LLP transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Marshall Wace, LLP holds 159,993 shares of ADCT stock, worth $633,572. This represents 0.0% of its overall portfolio holdings.
Number of Shares
159,993Holding current value
$633,572% of portfolio
0.0%Shares
9 transactions
Others Institutions Holding ADCT
# of Institutions
108Shares Held
67.3MCall Options Held
39.8KPut Options Held
68.4K-
Redmile Group, LLC San Francisco, CA15.7MShares$62 Million6.9% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.14MShares$32.2 Million0.06% of portfolio
-
Prosight Management, LP Dallas, TX7.47MShares$29.6 Million7.9% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.91MShares$23.4 Million0.81% of portfolio
-
Morgan Stanley New York, NY3.67MShares$14.5 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $307M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...